AstraZeneca Asks FDA to Authorize an Antibody Treatment to Prevent COVID-19
It said the treatment could be used in conjunction with vaccines
On Tuesday, AstraZeneca said it had asked the Food and Drug Administration (FDA) to grant emergency authorization for an antibody treatment to prevent COVID-19 in people who are at high risk of the disease. If authorized, it would become the first such preventive treatment to be available in the United States, the company said.
The company said in a statement that the treatment had reduced the risk of symptomatic COVID-19 by 77 percent in a trial in which most participants either had other medical conditions that placed them at greater risk of severe illness or were not producing sufficient antibodies after vaccination.
It said the treatment could be used in conjunction with vaccines in people with weaker immune systems. Other antibody treatments in use in the United States, including one developed by the drug maker Regeneron, have mainly been used to treat people who are already infected with the coronavirus.
Please select this link to read the complete article from The New York Times.